Cardlytics Inc (NASDAQ:CDLX) CFO David Thomas Evans Sells 1,500 Shares

Cardlytics Inc (NASDAQ:CDLX) CFO David Thomas Evans sold 1,500 shares of the business’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $25.18, for a total value of $37,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

David Thomas Evans also recently made the following trade(s):

  • On Monday, April 15th, David Thomas Evans sold 1,500 shares of Cardlytics stock. The stock was sold at an average price of $15.42, for a total value of $23,130.00.
  • On Friday, March 29th, David Thomas Evans sold 2,505 shares of Cardlytics stock. The stock was sold at an average price of $16.21, for a total value of $40,606.05.
  • On Tuesday, March 26th, David Thomas Evans sold 2,616 shares of Cardlytics stock. The stock was sold at an average price of $15.53, for a total value of $40,626.48.
  • On Thursday, March 21st, David Thomas Evans sold 2,584 shares of Cardlytics stock. The stock was sold at an average price of $15.72, for a total value of $40,620.48.

Shares of CDLX stock traded up $0.07 during trading hours on Friday, reaching $28.04. 337,912 shares of the company’s stock were exchanged, compared to its average volume of 314,550. The business’s 50 day moving average price is $25.36. The stock has a market cap of $631.27 million, a P/E ratio of -13.10 and a beta of 1.75. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.99. Cardlytics Inc has a fifty-two week low of $9.80 and a fifty-two week high of $30.38.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.31. Cardlytics had a negative return on equity of 84.02% and a negative net margin of 25.53%. The business had revenue of $35.99 million for the quarter, compared to the consensus estimate of $36.11 million. During the same period in the prior year, the firm posted ($0.35) earnings per share. The business’s quarterly revenue was up 10.0% on a year-over-year basis. On average, equities research analysts forecast that Cardlytics Inc will post -1.12 EPS for the current fiscal year.

Several brokerages have weighed in on CDLX. ValuEngine raised Xylem from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. SunTrust Banks restated a “buy” rating and set a $25.00 target price on shares of Cardlytics in a research report on Tuesday, May 21st. KeyCorp boosted their target price on Harsco from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, May 10th. William Blair started coverage on Cardlytics in a research report on Monday, July 1st. They set an “outperform” rating for the company. Finally, Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $22.71.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CDLX. New York State Common Retirement Fund increased its position in shares of Cardlytics by 80.0% in the 4th quarter. New York State Common Retirement Fund now owns 9,000 shares of the company’s stock valued at $97,000 after acquiring an additional 4,000 shares during the period. TIAA CREF Investment Management LLC acquired a new stake in Cardlytics during the 3rd quarter worth about $202,000. Gamco Investors INC. ET AL acquired a new stake in Cardlytics during the 1st quarter worth about $256,000. Marshall Wace LLP purchased a new stake in shares of Cardlytics during the 1st quarter worth about $336,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of Cardlytics during the 4th quarter worth about $383,000. 73.51% of the stock is currently owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: What is the Book Value of a Share?

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.